Lundbeck Gets Chelsea’s Northera At A Discount, But Also Gets Challenges
This article was originally published in The Pink Sheet Daily
Executive Summary
The Danish drugmaker will pay $530 million upfront, but analysts believe it will not have to pay out the $129 million in contingent value rights payments.